{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095433","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.326559+00:00","generated_at":"2026-05-31T10:10:54.130060+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kyverna Q2 net loss $28.8M; cash $346.2M; RMAT designations for KYV-101","bullets":["Q2 net loss $28.8M ($0.67 per share) vs $13.1M loss year ago.","Cash, equivalents & marketable securities $346.2M as of June 30, 2024.","No severe ICANS or CRS Grade ≥3 in 36 autoimmune patients treated with KYV-101.","100% manufacturing success for KYV-101 across 36 patients.","Received FDA RMAT designations for Stiff-Person Syndrome and Myasthenia Gravis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095433","json":"https://secwatch.observer/filing/0000950170-24-095433.json","markdown":"https://secwatch.observer/filing/0000950170-24-095433.md","text":"https://secwatch.observer/filing/0000950170-24-095433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024095433/0000950170-24-095433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024095433/kytx-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:10:54.130060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}